by Sabrina Ahle | Jun 14, 2021 | Myeloma News
Source: Multiple Myeloma – ASH Clinical News In our March 2021 issue, we reported on findings from a review article examining disparities in outcomes among patients with multiple myeloma (MM), in which the authors found that Hispanic and non-Hispanic Black patients...
by Sabrina Ahle | Jun 14, 2021 | Myeloma News
Source: Multiple Myeloma – ASH Clinical News According to a study published in Blood, older patients with multiple myeloma (MM) who are taking continuous lenalidomide-dexamethasone (Rd) may be able to switch to reduced-dose lenalidomide maintenance without...
by Sabrina Ahle | Jun 14, 2021 | Myeloma News
Source: Multiple Myeloma – ASH Clinical News The FDA has approved idecabtagene vicleucel (ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed or refractory...
by Sabrina Ahle | Jun 14, 2021 | Myeloma News
Source: Multiple Myeloma – ASH Clinical News Tandem high-dose influenza vaccination may result in more durable serologic immunity in patients with plasma cell dyscrasias (PCDs), compared with standard vaccination, according to findings published in Blood Advances....
by Sabrina Ahle | Jun 14, 2021 | Myeloma News
Source: Multiple Myeloma – ASH Clinical News Treatment with the B-cell maturation antigen−targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene ciloleucel (ide-cel) showed encouraging efficacy in patients with heavily pretreated relapsed and/or...
